Unlock News Summary by Subscribing to iPick.ai Premium!
Ask anything related to KOD. [ FAQ on what and how to ask] For non-KOD questions, click the logo in the upper-right corner to return to the main page and ask there.
Unlock YouTube Video by Subscribing to iPick.ai Premium!
Not available
Address: 1250 Page Mill Road, Palo Alto, CA, United States, 94304
Employees: 141
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), a bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Co-Founder, Chairman, CEO & President
Executive VP, CFO & Secretary
Chief Technology Officer
Chief Scientific Officer
Senior Vice President of Development
Senior Vice President of Chemical Development & Manufacturing
Chief Quality Officer
Chief Medical Officer
Senior VP of Biologics Development & Manufacturing
My Watchlist
